According to the FDA, between 25% and 30% of patients with advanced endometrial cancer have tumors carrying the dMMR signature. The GSK drug is a type of immunotherapy called a checkpoint inhibitor.

Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

Key Takeaways. Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median ...

Results showed that in the dMMR/MSI-H population (n=122), treatment with dostarlimab plus carboplatin-paclitaxel reduced the risk of disease progression by 71% vs placebo plus carboplatin ...

Opdivo (nivolumab) plus Yervoy (ipilimumab) improved progression-free survival (PFS) compared to Opdivo alone in patients with mismatch repair deficient (dMMR) or microsatellite instability-high ...

Keytruda was also studied in people with advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) endometrial cancer who had received previous treatment for their cancer.

PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer ...

Another study shows good results with neoadjuvant immunotherapy in patients with locally advanced dMMR/MSI-H colorectal cancer, leading the authors to suggest it as a new standard of care.

CHICAGO -- Single-agent dostarlimab (Jemperli) led to complete responses in 100% of a small group of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, allowing them to ...

Deficient MMR (dMMR) in colorectal cancer (CRC) occurs as a result of inherited or sporadic abnormalities. Phenotypic characteristics, such as proximal anatomical location, mucinous features ...